Understanding the role of neutrophil enzymes in a type of asthma with low inflammation
Asthma can be a challenging condition, and for some, called Type 2-low asthma, current treatments often don't work well. This study aims to understand why by looking closely at certain immune cells called neutrophils and the proteins they release. These cells might be causing damage in the airways and making this type of asthma worse. Participants will provide phlegm samples, have lung function tests, and fill out questionnaires. This will help researchers identify if a specific 'neutrophilic' form of asthma exists. The findings could pave the way for new medications to better control symptoms, reduce asthma attacks, and significantly improve the quality of life for those with Type 2-low asthma. This is an observational study, meaning no new drugs will be tested.
At a glance
What is this study about?
Asthma is a common lung condition that makes breathing difficult. While many people manage their asthma well with existing treatments, about one in ten have a type called Type 2-low asthma. This form is particularly hard to treat because standard medicines, like inhaled steroids and newer biological therapies, often don't help much. People with Type 2-low asthma tend to visit the hospital more, have more severe asthma attacks, and experience a lower quality of life.
Researchers believe that a possible reason for this difficult-to-treat asthma could be higher numbers of specific immune cells called neutrophils in the airways. When these neutrophils become active, they release proteins that can damage the lining of the airways and worsen inflammation. We already know from research into other lung conditions that medicines designed to block the activity of these neutrophils can help reduce flare-ups. However, these specific treatments haven't yet been studied in people with Type 2-low asthma.
This study is designed to investigate if these neutrophil proteins, especially one called neutrophil elastase, are indeed more common in people with Type 2-low asthma compared to those with other forms of asthma. By understanding this, the study hopes to lay the groundwork for developing new and more effective treatments. The ultimate goal is to improve how asthma symptoms are controlled, reduce the number of severe attacks, and significantly enhance the daily lives of people living with Type 2-low asthma.
Key takeaways
- This study focuses on Type 2-low asthma, which is hard to treat.
- It's an observational study, not testing new drugs.
- Researchers are looking at immune cells (neutrophils) in phlegm.
- Your participation helps understand asthma better for future treatments.
- You will provide phlegm samples, do lung tests, and complete questionnaires.
- The study runs from July 2026 to October 2027 at Ninewells Hospital.
Who may be eligible?
This study is looking for adults aged 18 or over who have moderate to severe asthma and receive treatment from NHS Tayside. You should have had a diagnosis of asthma for at least six months and be taking regular asthma medication, usually a combination inhaler.
There are certain reasons why you might not be able to join. For example, if you are currently taking asthma biologics or regular oral steroids, or have recently taken oral steroids for an asthma flare-up. You also can't participate if you have other serious lung conditions like severe emphysema or bronchiectasis, or if you've recently had a chest infection or asthma attack within the last month. We also can't include you if you're taking part in another clinical trial at the moment.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you have moderate to severe asthma, treated by NHS Tayside?
- Are you taking regular asthma medication (e.g., a combination inhaler)?
- Have you not received oral steroids for asthma in the last month?
- Do you NOT have other serious lung conditions like severe emphysema?
- Are you NOT currently part of another clinical trial?
What does participation involve?
This is an observational study, meaning we are not testing new drugs or treatments. If you take part, you will be asked to provide sputum (phlegm) samples. This is usually done by inhaling a saltwater solution through a nebuliser, which helps you produce the samples. You will also have standard lung function tests, which measure how well your lungs are working. Finally, you'll be asked to complete some questionnaires about your asthma symptoms and how your asthma affects your daily life. The study plans to run from July 2026 to October 2027.
Potential risks and benefits
Locations (1)
- Ninewells HospitalUnverifiedDundee, Scotland
Common questions
What is Type 2-low asthma?
It's a type of asthma that often doesn't respond well to standard treatments, making it particularly difficult to manage.
Will I receive a new treatment in this study?
No, this is an 'observational' study. We are not testing any new drugs or treatments, but rather observing and gathering information.
What does providing a sputum (phlegm) sample involve?
You will inhale a saltwater mist through a nebuliser, which helps you produce the phlegm samples needed for the study. It might cause some temporary coughing.
Who is funding this research?
The study is funded by NHS Tayside in the UK.
Can I leave the study if I change my mind?
Yes, you are free to withdraw from the study at any time without needing to give a reason.
How to find out more
Rory Chan
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.